Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments

Molecular Psychiatry

Volumn 7, Issue , 2002, Pages S71-S80

  Krystal, J H ^a,b,c   Sanacora, G ^a,b   Blumberg, H ^a,c   Anand, A ^a,c   Charney, D S ^a,c   Marek, G ^a,b   Epperson, C N ^a,b   Goddard, A ^a,b   Mason, G F ^a,b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University School of Medicine   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Anticonvulsant; Bipolar disorder; Depression; Magnetic resonance spectroscopy; Metabotropic glutamate receptor; N methyl D aspartate (NMDA); Panic disorder; Premenstrual dysphoric disorder; Serotonin 2A receptor; Voltage gated calcium channel

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; CALCIUM CHANNEL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

AFFECTIVE NEUROSIS; ARTICLE; CHANNEL GATING; DRUG MECHANISM; DYSPHORIA; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; PANIC; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; MODELS, NEUROLOGICAL; MOOD DISORDERS; SYNAPTIC TRANSMISSION;

EID: 0036212738     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4001021     Document Type: Article

References (129)

1. Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000; 61 (Suppl 6): 7-11.
2. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000; 61 (Suppl 6): 4-6.
3. Berman RM, Krystal JH, Charney DS. Mechanism of action of antidepressants: monoamine hypotheses and beyond. In: Watson SJ (ed). Biology of Schizophrenia and Affective Disease. American Psychiatric Press: Washington, DC, 1996, pp 295-368.
4. Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999; 46: 1181-1191.
5. Ikonomov OC, Manji HK. Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. Am J Psychiatry 1999; 156: 1506-1514.
6. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996; 29: 23-26.
7. Sanacora G, Mason GF, Krystal JH. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit Rev Neurobiol 2000; 14: 23-45.
8. Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME. A functional anatomical study of unipolar depression. J Neurosci 1992; 12: 3628-3641.
9. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996; 93: 3908-3913.
10. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry 2000; 157: 115-118.
11. Steffens DC, Byrum CE, McQuoid DR et al. Hippocampal volume in geriatric depression. Biol Psychiatry 2000; 48: 301-309.
12. Robinson RG, Chemerinski E, Jorge R. Pathophysiology of secondary depressions in the elderly. J Geriatr Psychiatry Neurol 1999; 12: 128-136.
13. Drevets WC, Price JL, Simpson JR Jr et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 386: 824-827.
14. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Nalt Acad Sci U S A 1998; 95: 13290-13295.
15. Rajkowska G, Miguel-Hidalgo JJ, Wei J et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45: 1085-1098.
16. Malandro MS, Kilberg MS. Molecular biology of mammalian amino acid transporters. Ann Rev Biochem 1996; 65: 305-336.
17. Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science 1999; 283: 496-497.
18. During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 1993; 341: 1607-1610.
19. Drevets WC. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci 1999; 877: 614-637.
20. Mayberg HS, Liotti M, Brannan SK et al. Reciprocal limbiccortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156: 675-682.
21. Blumberg HP, Stern E, Martinez D et al. Increased anterior cingulate and caudate activity in bipolar mania. Biol Psychiatry 2000; 48: 1045-1052.
22. Schell MJ, Brady RO Jr., Molliver ME, Snyder SH. D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J Neurosci 1997; 17: 1604-1615.
23. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000; 57: 925-935.
24. Cappiello A, Charney DS, Berman R et al. NMDA receptor function in major depression. Biol Psychiatry 1997; 41: 45S.
25. Nowak G, Ordway GA, Paul IA. Alterations in the N-methyl-Daspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995; 675: 157-164.
26. Mason GF, Sanacora G, Anand A et al. Cortical GABA reduced in unipolar, but not bipolar depression. Biol Psychiatry 2000; 47: 92S.
27. Mason GF, Gruetter R, Rothman DL, Behar KL, Shulman RG, Novotny EJ. Simultaneous determination of the rates of the TCA cycle, glucose utilization, alpha-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J Cereb Blood Flow Metab 1995; 15: 12-25.
28. Shen J, Petersen KF, Behar KL et al. Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc Nat Acad Sci U S A 1999; 96: 8235-8240.
29. Mason GF, Haga K, Appel M et al. Measuring cortical GABA levels and neurotransmitter turnover with 1H-MRS and 13C-MRS. Biol Psychiatry 2001; 49: 148S.
30. Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000; 47: 305-313.
31. Papp M, Moryl E. New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. Pol J Pharmacol 1993; 45: 549-553.
32. Wedzony K, Klimek V, Nowak G. Rapid down-regulation of betaadrenergic receptors evoked by combined forced swimming test and CGP 37849—a competitive antagonist of NMDA receptors. Pol J Pharmacol 1995; 47: 537-540.
33. Wedzony K, Mackowiak M, Czyrak A, Fijal K, Michalska B. Single doses of MK-801, a non-competitive antagonist of NMDA receptors, increase the number of 5-HT1A serotonin receptors in the rat brain. Brain Res 1997; 756: 84-91.
34. Pallotta M, Segieth J, Whitton PS. N-methyl-D-aspartate receptors regulate 5-HT release in the raphe nuclei and frontal cortex of freely moving rats: differential role of 5-HT1A autoreceptors. Brain Res 1998; 783: 173-178.
35. Lejeune F, Gobert A, Rivet JM, Millan MJ. Blockade of transmission at NMDA receptors facilitates the electrical and synthetic activity of ascending serotoninergic neurones. Brain Res 1994; 656: 427-431.
36. Martin P, Carlsson ML, Hjorth S. Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport 1998; 9: 2985-2988.
37. Nowak G, Redmond A, McNamara M, Paul IA. Swim stress increases the potency of glycine at the N-methyl-D-aspartate receptor complex. J Neurochem 1995; 64: 925-927.
38. Fitzgerald LW, Ortiz J, Hamedani AG, Nestler EJ. Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitizing agents. J Neurosci 1996; 16: 274-282.
39. Paul IA, Nowak G, Layer RT, Popik P, Skolnick P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994; 269: 95-102.
40. Reynolds IJ, Miller RJ. Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Br J Pharmacol 1988; 95: 95-102.
41. White G, Lovinger DM, Peoples RW, Weight FF. Inhibition of Nmethyl-D-aspartate activated ion current by desmethylimipramine. Brain Res 1990; 537: 337-339.
42. Crane GE. The psychotropic effect of cycloserine: a new use of an antibiotic. Compr Psychiatry 1961; 2: 51-59.
43. Monahan JB, Corpus VM, Hood WF, Thomas JW, Compton RP. Characterization of a [3H]glycine recognition site as a modulatory site of the N-methyl-D-aspartate receptor complex. J Neurochem 1989; 53: 370-375.
44. Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 1991; 30: 1167-1171.
45. Henderson G, Johnson JW, Ascher P. Competitive antagonists and partial agonists at the glycine modulatory site of the mouse Nmethyl-D-aspartate receptor. J Physiol 1990; 430: 189-212.
46. Priestley T, Kemp JA. Kinetic study of the interactions between the glutamate and glycine recognition sites on the N-methyl-Daspartic acid receptor complex. Mol Pharmacol 1994; 46: 1191-1196.
47. Crane GE. Cycloserine as an antidepressant agent. Am J Psychiatry 1959; 115: 1025-1026.
48. Krystal JH, Petrakis IL, D’Souza DC, Trevisan L, Krasnicki S, Charney DS. Interactive effects of high dose intravenous glycine and oral D-cycloserine in healthy human subjects. Biol Psychiatry 1997; 41 (Suppl): 23S.
49. Krystal JH, Karper LP, Seibyl JP et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
50. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry 1999; 32: 47-55.
51. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents—preclinical studies. Neurosci Biobehav Rev 1997; 21: 455-468.
52. Kornhuber J, Quack G, Danysz W et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995; 34: 713-721.
53. Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 1996; 8: 446-454.
54. Vale S, Espejel MA, Dominguez JC. Amantadine in depression. Lancet 1971; 2: 437.
55. Bode L, Dietrich DE, Stoyloff R, Emrich HM, Ludwig H. Amantadine and human Borna disease virus in vitro and in vivo in an infected patients with bipolar depression. Lancet 1997; 349: 958.
56. Rizzo M, Morselli PL. Amantadine-induced aggressiveness. Br Med J 1972; 3: 50.
57. Parkes JD, Zilkha KJ, Marsden P, Baxter RC, Knill-Jones RP. Aman tadine dosage in treatment of Parkinson’s disease. Lancet 1970; 1: 1130-1133.
58. Gortelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittel-Forschung 1992; 42: 904-913.
59. Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine—results of a phase II double-blind study. Pharmacopsychiatry 1988; 21: 144-146.
60. Berman RM, Cappiello A, Anand A, Oren D, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354.
61. Blumberg HP, Leung HC, Wexler B et al. Ventral prefrontal dysfunction in bipolar disorder: an fMRI study. Biol Psychiatry 2001; 49: 26S.
62. Starkstein SE, Robinson RG. Mechanism of disinhibition after brain lesions. J Nerv Ment Dis 1997; 185: 108-114.
63. Knight RT, Staines WR, Swick D, Chao LL. Prefrontal cortex regulates inhibition and excitation in distributed neural networks. Acta Psychologica 1999; 101: 159-178.
64. Blumberg HP, Stern E, Ricketts S et al. Rostral and orbital prefrontal cortex dysfunction in the manic state of bipolar disorder. Am J Psychiatry 1999; 156: 1986-1988.
65. Dixon JF, Hokin LE. Lithium acutely inhibits and chronically upregulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci U S A 1998; 95: 8363-8368.
66. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptormediated calcium influx. Proc Natl Acad Sci U S A 1998; 95: 2642-2647.
67. Manji HK, Lenox RH. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999; 46: 1328-1351.
68. Meldrum BS. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994; 44 (Suppl 8): S14-23.
69. Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 2000; 39: 2139-2146.
70. Lingamaneni R, Hemmings HC, Jr. Effects of anticonvulsants on veratridine-and KCl-evoked glutamate release from rat cortical synaptosomes. Neurosci Lett 1999; 276: 127-130.
71. Calabresi P, Centonze D, Marfia GA, Pisani A, Bernardi G. An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. Br J Pharmacol 1999; 126: 689-696.
72. Waldmeier PC, Martin P, Stocklin K, Portet C, Schmutz M. Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Naunyn-Schmiedebergs Arch Pharmacol 1996; 354: 164-172.
73. Waldmeier PC, Baumann PA, Wicki P, Feldtrauer JJ, Stierlin C, Schmutz M. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995; 45: 1907-1913.
74. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J Clin Psychiatry 1999; 60 (Suppl 2): 27-39; discussion 40-41, 113-116.
75. Jakab RL, Goldman-Rakic PS. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A 1998; 95: 735-740.
76. Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 2000; 31: 302-312.
77. Scruggs JL, Patel S, Bubser M, Deutch AY. DOI-induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons. J Neurosci (Online) 2000; 20: 8846-8852.
78. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 2000; 292: 76-87.
79. Marek GJ, McDougle CJ, Price LH, Seiden LS. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology 1992; 109: 2-11.
80. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000; 61: 638-642.
81. Keck PE Jr, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000; 61 (Suppl 4): 33-38.
82. Grunze HC, Rainnie DG, Hasselmo ME et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 1996; 16: 2034-2043.
83. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-2927.
84. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349-1352.
85. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug—sernyl. Arch Neurol Psychiatry 1959; 81: 363-369.
86. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997; 154: 805-811.
87. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6: 869-872.
88. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)-and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 1997; 7: 25-38.
89. Krystal JH, Belger A, Kirino E, Gore J, McCarthy G. Ketamine effects on the cortical processing of novelty in humans assessed with fMRI. Soc Neurosci Abstr 1998; 24: 104.7.
90. Anand A, Charney DS, Cappiello A, Berman RM, Oren DA, Krystal JH. Lamotrigine attenuates ketamine effects in humans: support for hyperglutamatergic effects of NMDA antagonists. Arch Gen Psychiatry 2000; 57: 270-276.
91. Krupitsky EM, Burakov AM, Romanova TN et al. Attenuation of ketamine effects by nimodipine in recently detoxified ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. Neuropsychopharmacology 2001; 25: 936-947.
92. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79-88.
93. Newcomer JW, Farber NB, Selke G, Melson AK, Jevtovic-Todorovic V, Olney JW. Guanabenz effects on NMDA antagonistinduced mental symptoms in human. Soc Neurosci Abstr 1998; 24: 211.2.
94. Giannini AJ, Pascarzi GA, Loiselle RH, Price WA, Giannini MC. Comparison of clonidine and lithium in the treatment of mania. Am J Psychiatry 1986; 143: 1608-1609.
95. Zubenko GS, Cohen BM, Lipinski JF Jr, Jonas JM. Clonidine in the treatment of mania and mixed bipolar disorder. Am J Psychiatry 1984; 141: 1617-1618.
96. Lahti AC, Weiler MA, Parwani A et al. Blockade of ketamineinduced psychosis with olanzepine. Schizophr Res 1999; 36: 310.
97. Vollenweider FX, Bachle D, Umbricht D, Geyer M, Hell D. Sertindole reduces S-ketamine induced attentional deficits in healthy volunteers. Biol Psychiatry 1999; 100S.
98. Krystal JH, Karper LP, Bennett A et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 1998; 135: 213-229.
99. Bovill JG, Clarke RSJ, Dundee JW, Pandit SK, Moore J. Effect of premedicants and supplements on ketamine anesthesia. Br J Anaesth 1971; 43: 600-608.
100. Bradwejn J, Shriqui C, Koszycki D, Meterissian G. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990; 10: 403-408.
101. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry 1992; 53: 47-52.
102. Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 1995; 34: 275-281.
103. Roy A, DeJong J, Lamparski D, George T, Linnoila M. Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables. Arch Gen Psychiatry 1991; 48: 428-432.
104. Rutherford LC, DeWan A, Lauer HM, Turrigiano GG. Brainderived neurotrophic factor mediates the activity-dependent regulation of inhibition in neocortical cultures. J Neurosci 1997; 17: 4527-4535.
105. Vaidya VA, Terwilliger RM, Duman RS. Role of 5-HT2A receptors in the stress-induced down-regulation of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 1999; 262: 1-4.
106. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999; 274: 6039-6042.
107. Mora A, Gonzalez-Polo RA, Fuentes JM, Soler G, Centeno F. Different mechanisms of protection against apoptosis by valproate and Li+. Eur J Biochem 1999; 266: 886-891.
108. Rothman DL, Petroff OA, Behar KL, Mattson RH. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci U S A 1993; 90: 5662-5666.
109. Petroff OA, Rothman DL. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin. Mol Neurobiol 1998; 16: 97-121.
110. Sanacora G, Mason GF, Rothman DL et al. Reduced cortical GABA levels in depressed patients determined by 1H-magnetic resonance spectroscopy. Arch Gen Psychiatry 1999; 56: 1043-1047.
111. Goddard AW, Mason GF, Rothman DL et al. Reduction in cortical GABA levels in panic disorder assessed using [1H] magnetic resonance spectroscopy. Arch Gen Psychiatry 2001; 58: 556-561.
112. Foley DL, Neale MC, Kendler KS. Reliability of a lifetime history of major depression: implications for heritability and co-morbidity. Psychol Med 1998; 28: 857-870.
113. Weissman MM, Wickramaratne P, Adams PB et al. The relationship between panic disorder and major depression. A new family study. Arch Gen Psychiatry 1993; 50: 767-780.
114. Epperson CN, Mason G, Rothman DR, Sanacora G, Krystal JH. GABA dysregulation in premenstrual dysphoric disorder. Soc Neurosci Abstr 1999; 25: 2227.
115. Monteleone P, Luisi S, Tonetti A et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000; 142: 269-273.
116. Bicikova M, Dibbelt L, Hill M, Hampl R, Starka L. Allopregnanolone in women with premenstrual syndrome. Horm Metab Res 1998; 30: 227-230.
117. Rapkin AJ, Morgan M, Goldman L, Brann DW, Simone D, Mahesh VB. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90: 709-714.
118. Schmidt PJ, Purdy RH, Moore PH Jr, Paul SM, Rubinow DR. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994; 79: 1256-1260.
119. Petty F, Sherman AD. GABAergic modulation of learned helplessness. Pharmacol Biochem Behav 1981; 15: 567-570.
120. Lloyd KG, Zivkovic B, Scatton B, Morselli PL, Bartholini G. The gabaergic hypothesis of depression. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 341-351.
121. Sackeim HA, Decina P, Prohovnik I, Malitz S, Resor SR. Anticonvulsant and antidepressant properties of electroconvulsive therapy: a proposed mechanism of action. Biol Psychiatry 1983; 18: 1301-1310.
122. Grahame-Smith DG. The neuropharmacological effects of electroconvulsive shock and their relationship to the therapeutic effect of electroconvulsive therapy in depression. Adv Biochem Psychopharmacol 1984; 39: 327-343.
123. Green AR, Vincent ND. The effect of repeated electroconvulsive shock on GABA synthesis and release in regions of rat brain. Br J Pharmacol 1987; 92: 19-24.
124. 1H-MRS. Scientific Abstracts from the 37th Annual Meeting of the American College of Neuropsychopahrmacology, Las Croabas, Puerto Rico. 1998, p 200.
125. Sanacora G, Mason GF, Rothman DL, Berman RM, Zimolo Z, Krystal JH. Cortical GABA concentrations are increased in depressed patients following treatment with selective serotonin reuptake inhibitors. Scientific Abstracts from the 39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR, 2000, p 200.
126. Petroff OA, Rothman DL, Behar KL, Mattson RH. Low brain GABA level is associated with poor seizure control. Ann Neurol 1996; 40: 908-911.
127. Petroff OA, Rothman DL, Behar KL, Collins TL, Mattson RH. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology 1996; 47: 1567-1571.
128. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-nobutyric acid in patients with epilepsy. Ann Neurol 1996; 39: 95-99.
129. Petroff OA, Hyder F, Mattson RH, Rothman DL. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology 1999; 52: 473-478.